You are here

Singlet Molecular Imaging Sensor for Photodynamic Therapy (7218-060)

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44CA119486-02
Agency Tracking Number: CA119486
Amount: $948,959.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
United States
DUNS: 073800062
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 () -
Business Contact
Phone: (978) 689-0003
Research Institution

DESCRIPTION (provided by applicant): Photodynamic therapy (PDT) is a promising cancer treatment. PDT uses the affinity of photosensitizers such as hematoporphyrin derivative (HPD) and other compounds to be selectively retained in malignant tumors. When tum
ors, pretreated with the photosensitizer (PS), are irradiated with visible light, a photochemical reaction occurs and tumor cells are destroyed. Oxygen molecules in the metastable singlet delta state O2(1 ) are believed to be the species that destroys canc
erous cells during PDT. An optically- based imaging device that can visualize spatial maps of both the singlet oxygen production and the location of the PS in a tumor during PDT would be a valuable tool for PDT research and more effective treatments. In a
Phase I program Physical Sciences Inc. (PSI) developed and demonstrated a 2D imaging system and successfully produced spatially resolved images of photosensitizers and singlet oxygen both in-vitro and in-vivo. The in-vivo images were from mice containing t
umor models. Based on these successful Phase I results, in Phase II, PSI proposes to design, build and test a complete and ruggedized 2D imaging sensor for simultaneous, co-registered singlet oxygen emission and PS fluorescence. The system will use a fiber
coupled diode laser for light irradiation and two CCD cameras with a spectral discrimination method. A novel, intensified, near-IR array camera will be used for the detection of singlet oxygen emission. The 2D spatially resolved image of singlet oxygen em
ission will be correlated with PS fluorescence obtained with a visible imaging camera. The system will be tested on in-vitro photosensitizer samples at PSI. Comprehensive in-vivo tests will also be performed on tumor models in laboratory rats with our coll
aborators at Dartmouth College. A fully developed instrument will be a valuable tool for several aspects of PDT research including: elucidating kinetic and physiological phenomena, assessing new photosensitizers targeted to specific tissue areas, correlati
ng photosensitizer concentrations with singlet oxygen production, and evaluating the relationship between singlet oxygen production with tumor regression. PUBLIC HEALTH RELEVANCE: This project will demonstrate a novel diagnostic for improving the treatment
of cancer by light activated cancer killing drugs. A successful program will produce high resolution images of the location of an excited form of oxygen (produced by the light activated drugs within tumors) that is responsible for killing the tumor. It wi
ll be a valuable research tool to develop new, more effective treatments.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government